Literature DB >> 22352683

Pain management in hematological patients with major organ dysfunctions and comorbid illnesses.

Pasquale Niscola1, Andrea Tendas, Marco Giovannini, Laura Scaramucci, Luca Cupelli, Michele Ferrannini, Gregorio Antonio Brunetti, Francesco Bondanini, Roberto Palumbo, Alessio Perrotti, Claudio Romani, Claudio Cartoni, Fabio Efficace, Paolo de Fabritiis.   

Abstract

BACKGROUND: Organ dysfunctions and medical complications, such as renal failure, liver impairment, coagulation disorders, cardiovascular and respiratory illnesses, may hamper an adequate pain management in haematological patients. AIM: To summarize current knowledge on pain management in hematological patients presenting major organ dysfunctions and comorbidity. We also attempted to provide recommendations to optimize analgesia and to minimize side effects in the setting of medically compromised and frail haematological patients.
METHODS: A systematic search of the literature, using relevant key words, was conducted in PubMed. RESULTS AND
CONCLUSIONS: Pain in hematological patients is a common symptom and is often multi-factorial. Most pharmacotherapeutic measures, including causal therapies, analgesics and adjuvant agents routinely applied in pain management, may also be used in the setting of clinical frailty and medical comorbidities; however, comprehensive clinical and functional patient's evaluations and a careful consideration of expected benefits and potential adverse events are required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22352683     DOI: 10.2174/187152512800388902

Source DB:  PubMed          Journal:  Cardiovasc Hematol Agents Med Chem        ISSN: 1871-5257


  1 in total

1.  Towards a better understanding of the relationship between side effects of analgesia and quality of life in patients with multiple myeloma.

Authors:  Pasquale Niscola; Agostina Siniscalchi; Andrea Tendas; Paolo de Fabritiis; Tommaso Caravita; Fabio Efficace
Journal:  Support Care Cancer       Date:  2015-08-04       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.